ConductScience.org, home

Paper12374981

The polycomb group protein EZH2 is involved in progression of prostate cancer.

Varambally S and 11 others. Nature, 2002. Cited by 2,226 papers, by iCite.

Cite this record

ConductScience Library. The polycomb group protein EZH2 is involved in progression of prostate cancer. Papers, record 12374981. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/12374981

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The polycomb group protein EZH2 is involved in progression of prostate cancer.
PubMed
Journal
Nature
PubMed
Year
2002
PubMed
Publication types
Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
2,226
iCite
Relative citation ratio, by iCite
38.4
iCite
Revised in PubMed
2024-05-14
PubMed

Authors12

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Varambally SSooryanarayana
2Dhanasekaran SMSaravana M
3Zhou MMing
4Barrette TRTerrence R
5Kumar-Sinha CChandan
6Sanda MGMartin G
7Ghosh DDebashis
8Pienta KJKenneth J
9Sewalt RGRichard G A B
10Otte APArie P
11Rubin MAMark A
12Chinnaiyan AMArul M

Source PubMed

Download CSV of authors

Topics22

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Drosophila ProteinsMajor topic
Gene Expression Regulation, NeoplasticMajor topic
Nuclear ProteinsMajor topic
Prostatic NeoplasmsMajor topic
Repressor ProteinsMajor topic
Biomarkers, Tumor
Disease Progression
Gene Expression Profiling
Gene Silencing
Genes, Tumor Suppressor
Humans
Male
Molecular Sequence Data
Oligonucleotide Array Sequence Analysis
Phenotype
Polycomb Repressive Complex 2
Predictive Value of Tests
RNA, Messenger
RNA, Small Interfering
Transfection
Treatment Outcome
Tumor Cells, Cultured

Source PubMed

Download CSV of topics

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in12374961Cancer. The silence of the genes.https://conductscience.org/library/papers/12374961

Source PubMed

Download CSV of comments and corrections

Cited by1,351

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2,226 citations.

PMIDTitleJournalYearIn PapersSource
42950024A systematic pan-cancer analysis of intratumoral microbiota-derived epitopes to inform cancer immunotherapy and prevention.Sci Adv2026https://conductscience.org/library/papers/42950024PubMed
42877356DNA Methylation and TMPRSS2-ERG Fusion Status in Patients with Prostate Cancer from The Republic of North Macedonia.Balkan J Med Genet2026https://conductscience.org/library/papers/42877356PubMed
42794930A Multiplex RT-QPCR Assay of ONECUT2, EZH2, and BRCA2 for the Detection of Clinically Significant Prostate Cancer in Needle Biopsies.Cancers (Basel)2026https://conductscience.org/library/papers/42794930PubMed
42761779Histone modifications: mechanisms, metabolic regulation, and therapeutic targeting in cancer.Precis Clin Med2026https://conductscience.org/library/papers/42761779PubMed
42754954Advancements and future directions in transforming therapies of prostate cancer.Chin Med J (Engl)2026https://conductscience.org/library/papers/42754954PubMed
42601451An EZH2-SREBP2 axis promotes cholesterol biosynthesis and represents a noncanonical vulnerability in tumorigenesis.Nat Cell Biol2026https://conductscience.org/library/papers/42601451PubMed
42599162EZH2 Inhibition and Myeloid Risk: A Feature of On-Target Biology.Clin Cancer Res2026https://conductscience.org/library/papers/42599162PubMed
42591989The molecular underpinnings of the immune landscape in prostate cancer: decoding a "cold" tumor.Front Oncol2026https://conductscience.org/library/papers/42591989PubMed
42589556WSB1-Mediated PSMA Ubiquitination Promotes Enzalutamide-Induced Neuroendocrine-like Transition in Patient-Derived Prostate Cancer Spheroids.Int J Mol Sci2026https://conductscience.org/library/papers/42589556PubMed
42589296Integrated miRNA Sequencing and Network Analysis Reveal a Molecular Continuum Between Peritumoral and Tumor Tissue in Prostate Cancer.Int J Mol Sci2026https://conductscience.org/library/papers/42589296PubMed
42553046NNMT Loss Drives Cancer Progression by enhancing SAM availability for mTORC1 Signaling and Chromatin Methylation.bioRxiv2026https://conductscience.org/library/papers/42553046PubMed
42443217Oncogenic Ras drives EED degradation and PRC2 dysfunction to promote aggressive squamous cell carcinoma.Nat Commun2026https://conductscience.org/library/papers/42443217PubMed
42260416Integrated multi-omics profiling uncovers the epigenetic, transcriptional, and metabolic landscape of prostate cancer progression.BMC Cancer2026https://conductscience.org/library/papers/42260416PubMed
42252277Neuroendocrine tumours through an epigenetic lens: Emerging insights for diagnosis and treatment.J Neuroendocrinol2026https://conductscience.org/library/papers/42252277PubMed
42225614Multi-omics analyses identify EZH2 as a central driver in rhabdomyosarcoma radioresistance and highlight Tazemetostat as an effective radiosensitizer in vitro and in vivo.Cell Death Dis2026https://conductscience.org/library/papers/42225614PubMed
42219643Ion chromatography-ultra-high-resolution mass spectrometry reveals EZH2-driven reprogramming of nucleic acid and protein methylation.Anal Chim Acta2026https://conductscience.org/library/papers/42219643PubMed
42213546Molecular determinants of AR-enhancer interaction and cistrome reprogramming in prostate cancer progression.Endocr Relat Cancer2026https://conductscience.org/library/papers/42213546PubMed
42211521The role of EZH2 dysregulation in the pathogenesis of B-cell lymphomas and its implications as a target therapy.Front Oncol2026https://conductscience.org/library/papers/42211521PubMed
42170760Interplay of the 3D genome and epigenome in androgen-driven prostate cancer.Epigenomics2026https://conductscience.org/library/papers/42170760PubMed
42140904NRF1 predominantly causes EZH2 overexpression in cancer cells.Cell Death Dis2026https://conductscience.org/library/papers/42140904PubMed

See all 1,351 cited byDownload CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
AMACR23600PubTator's text mininghttps://conductscience.org/library/genes/23600NCBI Gene
EZH22146PubTator's text mininghttps://conductscience.org/library/genes/2146NCBI Gene

Download CSV of genes

Data2

The data bank entries PubMed's record names. Trial numbers are under Trials.

Data bankAccessionSource
RefSeqNM_004456RefSeq
RefSeqNM_014324RefSeq

Download CSV of data

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • References
  • Drugs

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/12374981

GET https://conductscience.org/api/papers/v1/12374981/cited_by?page=2